A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed microinvasive or centrally obstructing non-small cell lung
cancer

- Squamous cell carcinoma

- Adenocarcinoma

- Large cell carcinoma

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 50-100% OR

- ECOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- WBC at least 2,000/mm^3

- Platelet count at least 50,000/mm^3

Hepatic:

- Bilirubin no greater than 3.0 mg/dL

- Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)

- SGOT no greater than 3 times ULN

- PT no greater than 1.5 times ULN

Renal:

- Creatinine no greater than 3.0 mg/dL

Pulmonary:

- No severe chronic obstructive pulmonary disease that would preclude study

Other:

- Not pregnant

- Fertile patients must use effective contraception

- No contraindications to bronchoscopy

- No porphyria

- No hypersensitivity to porphyrin or porphyrin-like compounds

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Prior biologic therapy for lung cancer allowed

Chemotherapy:

- At least 4 weeks since prior chemotherapy

- No concurrent chemotherapy

Endocrine therapy:

- Prior endocrine therapy for lung cancer allowed

Radiotherapy:

- At least 4 weeks since prior radiotherapy

- No concurrent external beam radiotherapy

Surgery:

- No concurrent surgery

Other:

- Prior therapy for lung cancer allowed